Addex Therapeutics Ltd - ADR

Name: Addex Therapeutics Ltd - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Addex Therapeutics Ltd - ADR

Stock Card

$3.92

$0.08 (2.08%)

As on 31-Aug-2026 16:00EDT

Market cap

$5 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.2

Div. Yield

0 %

Addex Therapeutics - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.71 High: 3.97

52 Week Range

Low: 0.00 High: 12.05

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.8
Debt to Equity

0
Book Value

$--
EPS

$-7.4
Face value

--
Shares outstanding

1,265,844

10 Years Aggregate

CFO

CHF-68.30 Mln

EBITDA

CHF-83.37 Mln

Net Profit

CHF-88.41 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Addex Therapeutics - ADR	-49.2	-29.9	-41.1	-50.4	-26.0	-54.2	--
BSE Sensex^*	-9.3	-1.6	2.7	-3.7	5.8	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
Addex Therapeutics - ADR	10.3	15.6	-52.0	-90.0	-53.1
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Addex Therapeutics - ADR

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs... include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Read more

Co-Founder, CEO & Director

Mr. Timothy Mark Dyer
Co-Founder, CEO & Director

Mr. Timothy Mark Dyer
Headquarters

Geneva
Website

https://www.addextherapeutics.com

FAQs for Addex Therapeutics - ADR

What is the current share price of Addex Therapeutics Ltd - ADR Today?

The share price of Addex Therapeutics Ltd - ADR is $3.92 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Addex Therapeutics Ltd - ADR has given a return of -26.02% in the last 3 years.

What is the current PB & PE ratio of Addex Therapeutics Ltd - ADR?

Since, TTM earnings of Addex Therapeutics Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of Addex Therapeutics Ltd - ADR is 1.19 times as on 28-Aug-2026, a 76 discount to its peers’ median range of 4.96 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-1.15	1.62
2024	0.99	0.72
2023	-0.57	5.28
2022	--	--
2021	--	--

What is the 52 Week High and Low of Addex Therapeutics Ltd - ADR?

The 52-week high and low of Addex Therapeutics Ltd - ADR are Rs 12.05 and Rs 0.00 as of 01-Sep-2026.

What is the market cap of Addex Therapeutics Ltd - ADR?

Addex Therapeutics Ltd - ADR has a market capitalisation of $ 5 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Addex Therapeutics Ltd - ADR?

Before investing in Addex Therapeutics Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.